Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Aneurysm | 15 | 2023 | 87 | 1.890 |
Why?
|
| Aortic Valve | 10 | 2021 | 190 | 1.840 |
Why?
|
| Aorta | 4 | 2016 | 114 | 1.420 |
Why?
|
| Heart Valve Diseases | 3 | 2021 | 95 | 1.170 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2021 | 43 | 1.160 |
Why?
|
| Registries | 15 | 2023 | 888 | 0.970 |
Why?
|
| Dilatation, Pathologic | 3 | 2015 | 31 | 0.530 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2017 | 176 | 0.460 |
Why?
|
| Aortic Aneurysm, Thoracic | 7 | 2011 | 116 | 0.440 |
Why?
|
| Aortic Valve Stenosis | 2 | 2017 | 189 | 0.430 |
Why?
|
| Echocardiography | 2 | 2021 | 501 | 0.390 |
Why?
|
| Acute Disease | 14 | 2023 | 671 | 0.330 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 313 | 0.300 |
Why?
|
| Middle Aged | 25 | 2021 | 17612 | 0.270 |
Why?
|
| Male | 29 | 2021 | 29889 | 0.230 |
Why?
|
| Female | 29 | 2021 | 32878 | 0.220 |
Why?
|
| Humans | 32 | 2023 | 63443 | 0.200 |
Why?
|
| Hospital Mortality | 9 | 2015 | 877 | 0.190 |
Why?
|
| Electric Countershock | 3 | 2008 | 101 | 0.180 |
Why?
|
| Dilatation | 1 | 2021 | 32 | 0.170 |
Why?
|
| Aged | 21 | 2017 | 14446 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2021 | 6658 | 0.170 |
Why?
|
| Aorta, Thoracic | 3 | 2011 | 84 | 0.170 |
Why?
|
| Treatment Outcome | 14 | 2017 | 5680 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1094 | 0.150 |
Why?
|
| Hematoma | 3 | 2014 | 80 | 0.140 |
Why?
|
| Heparin | 2 | 2008 | 116 | 0.130 |
Why?
|
| Fibrinolytic Agents | 2 | 2008 | 169 | 0.120 |
Why?
|
| Adult | 6 | 2021 | 16823 | 0.120 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 110 | 0.110 |
Why?
|
| Comorbidity | 3 | 2014 | 1120 | 0.110 |
Why?
|
| Atrial Fibrillation | 3 | 2008 | 834 | 0.110 |
Why?
|
| Survival Rate | 2 | 2013 | 851 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 21 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 49 | 0.100 |
Why?
|
| Prognosis | 3 | 2013 | 1748 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2011 | 150 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2013 | 94 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 112 | 0.090 |
Why?
|
| Enoxaparin | 2 | 2008 | 18 | 0.090 |
Why?
|
| Postoperative Complications | 5 | 2017 | 1308 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 2 | 2011 | 263 | 0.090 |
Why?
|
| Internationality | 2 | 2007 | 44 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 490 | 0.080 |
Why?
|
| Case Management | 3 | 2006 | 55 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2011 | 203 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 712 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 1644 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2010 | 103 | 0.070 |
Why?
|
| Time Factors | 4 | 2023 | 3768 | 0.070 |
Why?
|
| Renal Insufficiency | 2 | 2006 | 65 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2017 | 768 | 0.060 |
Why?
|
| Risk Factors | 7 | 2017 | 5353 | 0.060 |
Why?
|
| Sex Factors | 2 | 2006 | 978 | 0.060 |
Why?
|
| Hypotension | 3 | 2014 | 50 | 0.060 |
Why?
|
| Seasons | 1 | 2005 | 134 | 0.050 |
Why?
|
| Decision Trees | 1 | 2004 | 51 | 0.050 |
Why?
|
| Age Factors | 4 | 2014 | 1558 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2023 | 31 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2006 | 583 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 5462 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2011 | 2458 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2008 | 111 | 0.050 |
Why?
|
| Pain | 1 | 2004 | 406 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2005 | 382 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2003 | 484 | 0.040 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 264 | 0.040 |
Why?
|
| Disease Management | 2 | 2014 | 232 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 422 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2023 | 724 | 0.040 |
Why?
|
| Disease Progression | 1 | 2003 | 1172 | 0.040 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 141 | 0.040 |
Why?
|
| Marfan Syndrome | 2 | 2011 | 18 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1553 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 2 | 2008 | 107 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 418 | 0.030 |
Why?
|
| Shock | 2 | 2006 | 33 | 0.030 |
Why?
|
| Life Tables | 2 | 2006 | 23 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2008 | 568 | 0.030 |
Why?
|
| Europe | 2 | 2006 | 195 | 0.030 |
Why?
|
| United States | 4 | 2013 | 7842 | 0.030 |
Why?
|
| Spinal Cord Ischemia | 1 | 2014 | 16 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 66 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 730 | 0.030 |
Why?
|
| Syncope | 2 | 2004 | 42 | 0.030 |
Why?
|
| Cardiac Tamponade | 2 | 2004 | 15 | 0.030 |
Why?
|
| Cardiovascular Agents | 2 | 2006 | 104 | 0.030 |
Why?
|
| Antihypertensive Agents | 2 | 2006 | 167 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2008 | 1008 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2014 | 79 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2014 | 2079 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 199 | 0.020 |
Why?
|
| Biomarkers | 2 | 2008 | 1408 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2014 | 318 | 0.020 |
Why?
|
| Cause of Death | 1 | 2011 | 221 | 0.020 |
Why?
|
| Stents | 1 | 2014 | 502 | 0.020 |
Why?
|
| Global Health | 1 | 2011 | 183 | 0.020 |
Why?
|
| Incidence | 2 | 2005 | 1377 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2007 | 2570 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2008 | 3293 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2008 | 9 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2008 | 14 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2008 | 77 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2008 | 84 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 655 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 166 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2006 | 39 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2005 | 2680 | 0.020 |
Why?
|
| Japan | 1 | 2006 | 59 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 137 | 0.020 |
Why?
|
| Mortality | 1 | 2006 | 160 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 240 | 0.010 |
Why?
|
| Chronobiology Phenomena | 1 | 2005 | 2 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2004 | 14 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2006 | 267 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2006 | 153 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 59 | 0.010 |
Why?
|
| Systole | 1 | 2004 | 108 | 0.010 |
Why?
|
| Consciousness Disorders | 1 | 2004 | 10 | 0.010 |
Why?
|
| Diastole | 1 | 2004 | 91 | 0.010 |
Why?
|
| Creatinine | 1 | 2004 | 134 | 0.010 |
Why?
|
| Biological Clocks | 1 | 2005 | 70 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 36 | 0.010 |
Why?
|
| Chest Pain | 1 | 2004 | 84 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 608 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 373 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 321 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 291 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 641 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 266 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2006 | 512 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 512 | 0.010 |
Why?
|
| Hospitals | 1 | 2005 | 393 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 2002 | 61 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1276 | 0.010 |
Why?
|
| Hypertension | 1 | 2006 | 586 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1119 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2005 | 495 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 298 | 0.010 |
Why?
|
| Hospitalization | 1 | 2006 | 1364 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 2334 | 0.010 |
Why?
|
| Heart Failure | 1 | 2004 | 913 | 0.010 |
Why?
|
| Stroke | 1 | 2004 | 1196 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 2575 | 0.010 |
Why?
|